Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
Tag: Xywav
All
Latest
All
Latest
Xywav Helps Propel Jazz to Over $1 Billion in Q2 Revenues
Jazz reports second-quarter earnings, with growth driven in part by a 13% increase in Xywav sales.
All
Latest
Jazz Challenges FDA on Lumryz Approval, Avadel Responds
Jazz Pharmaceuticals is challenging the FDA in district court over the FDA’s recent approval of a competing new narcolepsy drug, Lumryz.
Jazz: Oxybate Enhances Sleep Quality in Narcolepsy Patients Regardless of Dosing Schedule
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read More
Low-Sodium Xywav Leads Jazz Pharma’s Oxybate Revenues
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read More
Xyrem Generic for Narcolepsy Launches in US
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read More
Physician Discovers Surprising Possible Side Effect of Xywav in Narcolepsy Patient
A patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read More
Jazz to Present Seven Abstracts on Idiopathic Hypersomnia and Narcolepsy
Jazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read More
Jazz Reports Continued Adoption of Xywav for Narcolepsy and IH
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read More
Jazz Updates Xyrem, Xywav Prescription Forms
On February 9, Jazz Pharmaceuticals plc made changes to its XYWAV and XYREM prescription forms to decrease prescriber confusion.
Read More
Xywav Eases Idiopathic Hypersomnia Symptoms, New Data Shows
New clinical trial data shows that the medication Xywav significantly reduced the long sleep duration and excessive daytime sleepiness that are typical hallmarks of the sleep disorder idiopathic hypersomnia.
Read More
FDA Grants Jazz Pharmaceuticals New Exclusivity Rights for Hypersomnia Medication
Jazz announced on Monday that the U.S. Food and Drug Administration granted them Orphan Drug Exclusivity for the medication Xywav for the treatment of idiopathic hypersomnia.
Read More
FDA Grants Orphan Drug Status to Xywav, Citing “Greatly Reduced Chronic Sodium Burden Compared to Xyrem”
The FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read MoreJazz Pharmaceuticals Shares Results from Sleep Medicine Research & Therapy Development
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read More
Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read More
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
A literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read More
Xywav Phase 3 Data Published in SLEEP
Results of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More
FDA Fast Tracks Xywav for Idiopathic Hypersomnia
“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read More